Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ: AQST )

3.520 -0.070 (-1.95%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 712,650
Open 3.610
Bid (Size) 3.500 (2)
Ask (Size) 3.650 (40)
Prev. Close 3.590
Today's Range 3.460 - 3.640
52wk Range 1.950 - 6.230
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside. 
Via Benzinga

Performance

YTD
+75.12%
+75.12%
1 Month
-26.82%
-26.82%
3 Month
-30.16%
-30.16%
6 Month
+52.38%
+52.38%
1 Year
+76.00%
+76.00%

More News

Read More
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
Via Benzinga
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.